相关实验视频

Updated: Jun 12, 2025

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

托弗森用于SOD1 ALS的治疗

William H Everett^1,2, Robert C Bucelli¹

¹Department of Neurology, Washington University School of Medicine, Saint Louis, MO 63110, USA.

Neurodegenerative disease management

|September 27, 2024

概括

托弗森是一种针对肌缩侧面硬化症 (ALS) 的新疗法,其向的是SOD1突变. 虽然III期试验失败了其主要目标,但进一步的数据表明,它可能会减缓SOD1-ALS患者的疾病进展.

科学领域:

神经退行性疾病的神经退行性疾病
阿尔茨海默病的遗传学
橄核酸的治疗药物

背景情况:

肌缩侧面硬化症 (ALS) 是一种复杂的神经退行性疾病,患者群体异质,使临床试验设计复杂化.
基因突变,特别是在SOD1中,为ALS提供了更均的治疗策略的目标.
功能获取的SOD1突变是已知的家族性ALS的原因,使SOD1成为基因沉默疗法的可行目标.

研究的目的:

为了评估tofersen的疗效,一个反感性寡核酸,在治疗SOD1突变ALS.
评估托弗森对ALS生物标志物和疾病进展的影响.
探索针对特定ALS亚型的向基因疗法的潜力.

主要方法:

托弗森是一种反感性寡核酸,用于减少SOD1基因表达.
作用机制是SOD1mRNA的RNA酶介导的降解.
为了收集数据,进行了III期试验和随后的开放式扩展.

主要成果:

托弗森对ALS生物标志物表现出显著影响.
第三阶段试验的主要终点未达到.
开放式扩展数据表明,SOD1-ALS患者的疾病进展减缓.

结论:

使用托弗森的向基因降低疗法显示,它有望减缓SOD1-ALS的疾病进展.
尽管在最初的试验中没有达到主要终点,但托弗森的生物标志物效应和观察到的进展减缓需要进一步调查.
反感性寡核酸治疗代表了ALS的基因定义亚型的潜在治疗途径.

关键词:

降解MRNA的降解在SOD1中,SOD1是SOD1.骨髓缩侧面硬化症 (ALS) 是一种这是一种反意义的寡核酸.埃达拉沃尼是一个人瑞卢 (riluzole) 是一种药物.二甲酸 - 二甲酸 - 二甲酸 - 二甲酸这就是为什么我们要去fersen.

更多相关视频

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

$MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor$ 05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

相关概念视频

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...